Your browser is no longer supported. Please, upgrade your browser.
Settings
RAPT [NASD]
RAPT Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.44 Insider Own0.30% Shs Outstand29.49M Perf Week-3.53%
Market Cap951.70M Forward P/E- EPS next Y-3.25 Insider Trans-81.42% Shs Float28.76M Perf Month-21.76%
Income-64.00M PEG- EPS next Q-0.90 Inst Own88.50% Short Float3.48% Perf Quarter-16.52%
Sales4.40M P/S216.30 EPS this Y-16.00% Inst Trans-1.10% Short Ratio3.92 Perf Half Y62.93%
Book/sh6.85 P/B4.39 EPS next Y-23.90% ROA-38.00% Target Price60.29 Perf Year38.14%
Cash/sh6.66 P/C4.51 EPS next 5Y- ROE-41.60% 52W Range14.89 - 43.26 Perf YTD52.20%
Dividend- P/FCF- EPS past 5Y- ROI-52.00% 52W High-30.51% Beta-
Dividend %- Quick Ratio16.90 Sales past 5Y- Gross Margin- 52W Low101.88% ATR2.25
Employees81 Current Ratio16.90 Sales Q/Q-33.30% Oper. Margin- RSI (14)35.60 Volatility8.42% 6.34%
OptionableYes Debt/Eq0.00 EPS Q/Q-5.70% Profit Margin- Rel Volume4.20 Prev Close32.21
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume255.28K Price30.06
Recom1.90 SMA20-14.89% SMA50-10.60% SMA2006.24% Volume1,071,174 Change-6.67%
Aug-12-21Initiated SVB Leerink Outperform $49
Jun-21-21Initiated Piper Sandler Overweight $61
Jun-01-20Initiated H.C. Wainwright Buy $40
May-19-20Initiated Cantor Fitzgerald Overweight $37
Apr-13-20Initiated ROTH Capital Buy $38
Nov-25-19Initiated Wells Fargo Outperform $33
Nov-25-19Initiated UBS Buy $26
Nov-25-19Initiated BMO Capital Markets Outperform $35
Nov-29-21 03:04PM  
Nov-10-21 06:05PM  
04:05PM  
Nov-09-21 04:01PM  
Nov-08-21 03:00PM  
08:00AM  
Oct-29-21 09:33AM  
Oct-25-21 04:10PM  
Oct-18-21 08:00AM  
Sep-30-21 09:15AM  
Sep-23-21 11:15AM  
Sep-20-21 08:00AM  
08:00AM  
Sep-10-21 04:59PM  
Sep-03-21 08:00AM  
Aug-11-21 08:00AM  
Aug-05-21 03:01PM  
Jul-28-21 01:08PM  
Jul-22-21 06:11AM  
Jun-18-21 12:24PM  
Jun-16-21 11:49AM  
06:55AM  
Jun-15-21 11:07PM  
02:07PM  
01:26PM  
08:40AM  
Jun-14-21 04:01PM  
12:44PM  
08:00AM  
07:11AM  
Jun-13-21 04:00PM  
Jun-07-21 08:46AM  
May-20-21 04:00PM  
May-19-21 08:36AM  
May-11-21 08:00AM  
May-06-21 03:01PM  
Apr-12-21 07:49AM  
Apr-08-21 05:02AM  
Mar-22-21 08:00AM  
Mar-11-21 08:00AM  
Mar-10-21 04:30PM  
Mar-03-21 08:00AM  
Feb-22-21 09:47AM  
04:11AM  
Feb-19-21 08:00AM  
Jan-07-21 04:30AM  
Jan-05-21 08:00AM  
Dec-28-20 10:16AM  
Dec-15-20 11:26PM  
Nov-23-20 08:00AM  
01:24AM  
Nov-16-20 08:00AM  
07:30AM  
Nov-15-20 07:30AM  
Nov-13-20 08:00AM  
Nov-11-20 09:43AM  
Oct-14-20 08:00AM  
Sep-27-20 10:25AM  
Sep-03-20 08:32AM  
08:00AM  
Sep-01-20 02:53PM  
Aug-13-20 10:47AM  
Aug-05-20 08:00AM  
Jul-23-20 08:14PM  
Jul-02-20 11:24AM  
Jun-18-20 04:05PM  
Jun-17-20 08:00AM  
Jun-04-20 07:49AM  
May-29-20 08:00AM  
May-26-20 08:00AM  
May-19-20 07:47AM  
May-18-20 07:55AM  
May-17-20 10:38AM  
May-15-20 08:00AM  
May-14-20 08:00AM  
08:00AM  
May-12-20 08:00AM  
Mar-30-20 08:00AM  
Mar-04-20 08:00AM  
Feb-19-20 08:00AM  
Feb-07-20 06:45AM  
Feb-04-20 05:43PM  
Jan-31-20 11:27AM  
Jan-07-20 08:00AM  
Dec-16-19 08:00AM  
Dec-11-19 08:00AM  
Dec-10-19 08:00AM  
Dec-04-19 08:00AM  
07:06AM  
Dec-03-19 04:05PM  
03:29PM  
Nov-11-19 10:56AM  
Oct-30-19 08:49PM  
Jul-30-19 03:25PM  
Jul-28-19 02:08PM  
Jul-05-19 05:24PM  
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Robbins WendyeDirectorOct 18Buy30.7050015,3509,300Oct 19 11:33 AM
Robbins WendyeDirectorOct 13Buy29.6940011,8768,800Oct 15 06:25 PM
HO WILLIAMChief Medical OfficerOct 13Sale29.693,00089,07060,106Oct 14 01:16 PM
Brockstedt Dirk G.Chief Scientific OfficerOct 11Option Exercise6.182,64716,35822,459Oct 12 02:48 PM
Brockstedt Dirk G.Chief Scientific OfficerOct 11Sale30.782,64781,47519,812Oct 12 02:48 PM
COLUMN GROUP II, LP10% OwnerSep 27Option Exercise26.939,239248,8187,500Sep 29 04:58 PM
COLUMN GROUP II, LP10% OwnerSep 27Sale34.579,239319,3970Sep 29 04:58 PM
HO WILLIAMChief Medical OfficerSep 20Sale40.002,00080,00063,106Sep 22 06:27 PM
HO WILLIAMChief Medical OfficerSep 17Sale38.972,00077,93063,106Sep 20 01:58 PM
COLUMN GROUP II, LP10% OwnerSep 15Sale37.3533,5351,252,4180Sep 16 05:16 PM
COLUMN GROUP II, LP10% OwnerSep 14Sale36.94147,6765,454,8000Sep 16 05:16 PM
COLUMN GROUP II, LP10% OwnerSep 13Sale35.2714,317504,94336,633Sep 14 05:31 PM
Brockstedt Dirk G.Chief Scientific OfficerSep 10Option Exercise6.182,64816,36522,460Sep 13 01:29 PM
Brockstedt Dirk G.Chief Scientific OfficerSep 10Sale35.782,64894,74519,812Sep 13 01:29 PM
COLUMN GROUP II, LP10% OwnerSep 10Sale35.1921,738765,00741,421Sep 14 05:31 PM
HO WILLIAMChief Medical OfficerSep 08Sale36.043,000108,12065,106Sep 09 07:36 PM
COLUMN GROUP II, LP10% OwnerSep 02Sale35.4337,1011,314,5520Sep 03 04:09 PM
COLUMN GROUP II, LP10% OwnerSep 01Sale35.2331,7491,118,59218,545Sep 03 04:09 PM
Robbins WendyeDirectorAug 24Buy30.9952516,2702,000Aug 25 09:08 PM
COLUMN GROUP II, LP10% OwnerAug 24Sale31.4222,867718,4130Aug 24 08:52 PM
Robbins WendyeDirectorAug 23Buy31.391,47546,2951,475Aug 25 09:08 PM
COLUMN GROUP II, LP10% OwnerAug 23Sale31.3468,3402,141,57011,418Aug 24 08:52 PM
Robbins WendyeDirectorAug 20Buy29.5360017,7168,400Aug 23 07:04 PM
COLUMN GROUP II, LP10% OwnerAug 20Sale30.084,539136,53334,076Aug 24 08:52 PM
HO WILLIAMChief Medical OfficerAug 16Sale32.071,00032,07068,106Aug 17 07:24 PM
Brockstedt Dirk G.Chief Scientific OfficerAug 11Option Exercise6.182,64716,35822,459Aug 12 05:27 PM
Brockstedt Dirk G.Chief Scientific OfficerAug 11Sale31.192,64782,56019,812Aug 12 05:27 PM
HO WILLIAMChief Medical OfficerAug 06Option Exercise12.003,69044,28069,106Aug 09 01:28 PM
HO WILLIAMChief Medical OfficerAug 04Option Exercise6.246944,33165,416Aug 06 01:22 PM
HO WILLIAMChief Medical OfficerAug 02Sale30.521,00030,52064,722Aug 03 06:05 PM
HO WILLIAMChief Medical OfficerJul 23Option Exercise6.268,19351,28365,722Jul 26 03:59 PM
HO WILLIAMChief Medical OfficerJul 15Sale30.231,00030,23057,529Jul 16 01:00 PM
Brockstedt Dirk G.Chief Scientific OfficerJul 12Option Exercise6.182,64816,36522,460Jul 13 02:35 PM
Brockstedt Dirk G.Chief Scientific OfficerJul 12Sale33.532,64888,78719,812Jul 13 02:35 PM
Robbins WendyeDirectorJul 07Buy30.181,00030,1807,800Jul 08 01:32 PM
HO WILLIAMChief Medical OfficerJul 01Sale31.751,00031,75058,529Jul 02 12:49 PM
Robbins WendyeDirectorJun 16Buy31.615158305Jun 21 05:06 PM
Robbins WendyeDirectorJun 16Buy31.5470022,0796,800Jun 21 05:06 PM
HO WILLIAMChief Medical OfficerJun 15Sale43.261,00043,26059,529Jun 17 01:23 PM
HO WILLIAMChief Medical OfficerJun 14Sale40.002,00080,00060,529Jun 16 06:53 PM
Brockstedt Dirk G.Chief Scientific OfficerJun 11Option Exercise6.182,64716,35822,459Jun 15 08:51 PM
Brockstedt Dirk G.Chief Scientific OfficerJun 11Sale18.552,64749,10219,812Jun 15 08:51 PM
HO WILLIAMChief Medical OfficerJun 01Sale19.501,00019,50062,529Jun 02 05:39 PM
HO WILLIAMChief Medical OfficerMay 17Sale19.871,00019,87063,529May 19 04:36 PM
Brockstedt Dirk G.Chief Scientific OfficerMay 11Option Exercise6.182,64816,36522,460May 13 07:32 PM
Brockstedt Dirk G.Chief Scientific OfficerMay 11Sale18.192,64848,16719,812May 13 07:32 PM
Brockstedt Dirk G.Chief Scientific OfficerMay 05Sale21.562,08444,93119,812May 06 06:20 PM
HO WILLIAMChief Medical OfficerMay 03Sale22.041,00022,04064,529May 05 02:06 PM
HO WILLIAMChief Medical OfficerApr 15Sale21.141,00021,14063,445Apr 16 02:11 PM
Robbins WendyeDirectorApr 13Buy19.4670013,6206,100Apr 14 09:03 PM
Robbins WendyeDirectorApr 09Buy21.0480016,8311,300Apr 13 07:18 PM
Robbins WendyeDirectorApr 09Buy21.1260012,6745,400Apr 13 07:18 PM
HO WILLIAMChief Medical OfficerMar 15Sale21.911,00021,91065,445Mar 17 12:58 PM
HO WILLIAMChief Medical OfficerMar 01Sale18.601,00018,60066,445Mar 02 12:47 PM
Brockstedt Dirk G.Chief Scientific OfficerFeb 16Option Exercise6.289,87762,02929,689Feb 17 09:36 PM
HO WILLIAMChief Medical OfficerFeb 16Sale21.811,00021,81067,445Feb 17 09:39 PM
Brockstedt Dirk G.Chief Scientific OfficerFeb 16Sale21.229,877209,59019,812Feb 17 09:36 PM
HO WILLIAMChief Medical OfficerFeb 01Sale19.991,00019,99066,414Feb 02 07:27 PM
HO WILLIAMChief Medical OfficerJan 15Sale21.051,00021,05067,414Jan 15 08:52 PM
Brockstedt Dirk G.Chief Scientific OfficerJan 06Sale19.681,17923,20317,556Jan 06 08:48 PM
Brockstedt Dirk G.Chief Scientific OfficerJan 05Sale19.7682116,22518,735Jan 06 08:48 PM
HO WILLIAMChief Medical OfficerJan 04Sale19.751,00019,75068,414Jan 04 08:04 PM
Brockstedt Dirk G.Chief Scientific OfficerDec 30Option Exercise6.189,30057,47419,556Dec 31 06:09 PM
HO WILLIAMChief Medical OfficerDec 15Sale24.551,00024,55069,414Dec 15 09:01 PM